Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma
The lung adenocarcinoma organoid model accurately simulates drug sensitivity and the evolution of drug resistance, providing a highly predictive <i>in vitro</i> platform for optimizing individualized chemotherapy regimens. This model is anticipated to reduce the costs associated with trial-and-error in clinical settings and to advance the development of precision tumor therapies. Keywords Lung Cancer, Organoid Model, Chemotherapy Response, Resistance Evolution, Clinical Prediction, Precision Oncology.
Authors
- Wen Chen (ORCID: https://orcid.org/0000-0002-6603-0056)
- Huifeng Liu (ORCID: https://orcid.org/0000-0003-4786-7659)
- Yuyu Li (ORCID: https://orcid.org/0000-0002-3984-0889)
- Xiaoyun Zhang (ORCID: https://orcid.org/0000-0002-8994-1012)
- Won Joon Yun (ORCID: https://orcid.org/0000-0003-0405-8843)
- Xiao Li (ORCID: https://orcid.org/0000-0002-6078-4025)
- Yanlei Ge
Institutions
- Hebei North University (CN)
- Chinese PLA General Hospital (CN)
- North China University of Science and Technology Affiliated Hospital (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3389/fcell.2025.1639922
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00